Genotropin (somatropin)

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Short Stature Born Small for Gestational Age (SGA)

Conditions

Short Stature Born Small for Gestational Age (SGA)

Trial Timeline

Oct 1, 2002 → Aug 1, 2015

NCT ID

NCT01859949

About Genotropin (somatropin)

Genotropin (somatropin) is a approved stage product being developed by Pfizer for Short Stature Born Small for Gestational Age (SGA). The current trial status is completed. This product is registered under clinical trial identifier NCT01859949. Target conditions include Short Stature Born Small for Gestational Age (SGA).

What happened to similar drugs?

4 of 14 similar drugs in Short Stature Born Small for Gestational Age (SGA) were approved

Approved (4) Terminated (2) Active (10)

✅Growth HormoneEli LillyApproved

✅Somatotropin growth hormone recombinant humanPfizerApproved

✅GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatmentPfizerApproved

✅Nutropin [Somatropin (rDNA origin) for injection]IpsenApproved

🔄somatropin + leuprorelinEli LillyPhase 3

🔄Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth HormoneAstraZenecaPhase 3

🔄Saizen® + Saizen®MerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01859949	Approved	Completed	Oct 1, 2002	Aug 1, 2015	Short Stature Born Small for Gestational Age (SGA)

Competing Products

20 competing products in Short Stature Born Small for Gestational Age (SGA)

See all competitors

Product	Company	Stage	Hype Score
somatropin + leuprorelin	Eli Lilly	Phase 3	40
Growth Hormone	Eli Lilly	Approved	35
Pancreatic Enzyme	AbbVie	Phase 2	35
Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone	AstraZeneca	Phase 3	40
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)	Merck	Phase 1	29
Saizen® + Saizen®	Merck	Phase 3	40
r-metHuLeptin	Amgen	Phase 1	29
Somapacitan + Norditropin®	Novo Nordisk	Phase 2	39
Somatotropin growth hormone recombinant human	Pfizer	Approved	43
Genotropin + Genotropin	Pfizer	Phase 3	40
GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment	Pfizer	Approved	43
Genotropin	Pfizer	Phase 2/3	38
glepaglutide	Zealand Pharma	Phase 3	41
Glepaglutide	Zealand Pharma	Phase 3	41
ZP1848	Zealand Pharma	Phase 2	32
glepaglutide + Placebo	Zealand Pharma	Phase 3	37
Glepaglutide	Zealand Pharma	Phase 3	37
Glepaglutide 10 mg	Zealand Pharma	Phase 3	44
Glepaglutide	Zealand Pharma	Phase 3	44
Nutropin [Somatropin (rDNA origin) for injection]	Ipsen	Approved	32